Info: Read More
  • ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  •   
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Science | Nature | Cell | View More
    Natural Products
    Farnesol
    Farnesol
    Information
    CAS No. 4602-84-0 Price $30 / 20mg
    Catalog No.CFN70109Purity>=98%
    Molecular Weight222.3Type of CompoundSesquiterpenoids
    FormulaC15H26OPhysical DescriptionOil
    Download     COA    MSDSSimilar structuralComparison
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $8.9 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Kyung Hee University (Korea)
  • University of Auckland (New Zealand)
  • Charles Sturt University (Denmark)
  • Colorado State University (USA)
  • Kazusa DNA Research Institute (Japan)
  • Leibniz Institute of Plant Bioc... (Germany)
  • University of Canterbury (New Zealand)
  • Guangzhou Institutes of Biomedi... (China)
  • National Chung Hsing University (Taiwan)
  • University of Virginia (USA)
  • Uniwersytet Gdański (Poland)
  • More...
  • Package
    Featured Products
    Cimicidanol 3-O-alpha-L-arabinoside

    Catalog No: CFN90863
    CAS No: 161207-05-2
    Price: $288/10mg
    Oroxylin A 7-O-beta-D-glucuronide

    Catalog No: CFN90191
    CAS No: 36948-76-2
    Price: $318/20mg
    Ganoderic acid S

    Catalog No: CFN99066
    CAS No: 104759-35-5
    Price: $568/5mg
    Poncirin

    Catalog No: CFN90448
    CAS No: 14941-08-3
    Price: $218/20mg
    Gnetol

    Catalog No: CFN92425
    CAS No: 86361-55-9
    Price: $218/5mg
    Chlorogenic acid

    Catalog No: CFN99116
    CAS No: 327-97-9
    Price: $30/20mg
    20-Deoxocarnosol

    Catalog No: CFN92175
    CAS No: 94529-97-2
    Price: $463/5mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Sesquiterpenoids Compound Library
  • PPAR Inhibitor Library
  • Estrogen receptor Inhibitor Library
  • cAMP Inhibitor Library
  • AP-1 Inhibitor Library
  • Antifection Inhibitor Library
  • Biological Activity
    Description: Farnesol has anti-bacterial activity, it inhibits PQS production in Pseudomonas aeruginosa, it promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human β-defensin 2 production.Farnesol stimulates differentiation in Epidermal Keratinocytes via PPARα. It stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
    Targets: Antifection | AP-1 | PPAR | cAMP | Farnesoid X receptor | Estrogen receptor
    In vitro:
    Journal of Biological Chemistry, 2000, 275(15):11484-11491.
    Farnesol Stimulates Differentiation in Epidermal Keratinocytes via PPARα.[Reference: WebLink]
    The isoprenoids Farnesol and juvenile hormone III (JH), metabolites of the cholesterol biosynthetic pathway, have been shown to stimulate fetal epidermal development in rodents.
    METHODS AND RESULTS:
    In this study we determined whether this effect might be attributed to a direct induction of keratinocytes differentiation and examined the mechanisms responsible for these effects. Rates of cornified envelope formation, a marker of keratinocyte terminal differentiation, as well as protein and mRNA levels of two proteins required for cornified envelope formation, involucrin (INV) and transglutaminase, increased 2- to 3-fold in normal human keratinocytes (NHK) treated with either Farnesol or JH, even at low calcium concentrations (0.03 mm), which otherwise inhibit differentiation. In contrast, neither cholesterol nor mevalonate affected INV or transglutaminase mRNA levels. Effects of Farnesol and JH on INV and transglutaminase mRNA levels were additive with high calcium concentrations (1.2 mm) that independently stimulate keratinocyte differentiation. In contrast, keratinocyte DNA synthesis was inhibited by these compounds. Both Farnesol and JH stimulated INV and transglutaminase promoter activity, suggesting regulation at the transcriptional level. A series of truncation and deletion experiments revealed a Farnesol-responsive region (−2452 to −1880 base pairs (bp)) in the INV gene. This region contained an AP-1 site. A single base pair mutation of the AP-1 site at −2116 to −2110 bp abolished Farnesol responsiveness, identical to effects by peroxisome proliferator-activated receptor (PPARα) activators. Farnesoid X-activated receptor mRNA was not detected in NHK, but Farnesol treatment increased activities of both a PPAR response element and PPARα mRNA levels in NHK. Furthermore, the increase in PPRE activity by Farnesol was dependent upon PPARα in CV-1 cells. Finally, topical applications of Farnesol increased mRNA and protein levels of the differentiation-specific genes, profilaggrin and loricrin, determined by immunohistochemistry and in situhybridization, in wild-type but not in PPARα−/− murine epidermis.
    CONCLUSIONS:
    These findings suggest a novel role for selected isoprenoid cholesterol intermediates in the regulation of differentiation-specific gene transcription and a convergence of PPARα with the cholesterol synthetic pathway.
    Molecular Microbiology, 2008,67(1):47-62.
    Farnesol and dodecanol effects on the Candida albicans Ras1‐cAMP signalling pathway and the regulation of morphogenesis.[Reference: WebLink]

    METHODS AND RESULTS:
    Candida albicans hypha formation which has been stimulated via the Ras1‐cAMP‐Efg1 signalling cascade is inhibited by Farnesol, a C. albicans autoregulatory factor, and small molecules such as dodecanol. In cultures containing Farnesol or dodecanol, hypha formation was restored upon addition of dibutyryl‐cAMP. The CAI4‐Ras1G13V strain, which carries a dominant‐active variant of Ras1 and forms hyphae in the absence of inducing stimuli, grew as yeast in medium with Farnesol or dodecanol; the heat shock sensitivity of the CAI4‐Ras1G13V strain was also suppressed by these compounds. Neither Pde1 nor Pde2 was necessary for the repression of hyphal growth by Farnesol or dodecanol. Two transcripts, CTA1 and HSP12 , which are at higher levels upon mutation of Ras1 or Cdc35, were increased in abundance in cells grown with Farnesol or dodecanol. Microscopic analysis of strains carrying CTA1 and HWP1 promoter fusions grown with intermediate concentrations of Farnesol or dodecanol indicated a link between cells with the increased expression of cAMP‐repressed genes and cells repressed for hypha formation.
    CONCLUSIONS:
    Because several cAMP‐controlled outputs are affected by Farnesol and dodecanol, our findings suggest that these compounds impact activity of the Ras1‐Cdc35 pathway, thus leading to an alteration of C. albicans morphology.
    Cytokine, 2009, 45(2):132-140.
    Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human β-defensin 2 production.[Pubmed: 19121950]
    Farnesol, a quorum-sensing molecule, regulates virulence and morphogenesis in Candida albicans and is involved in various human pathologies including oral candidiasis. Oral epithelial cells are involved in innate immunity against Candida infections via Toll-like receptors (TLRs) and inflammatory mediators.
    METHODS AND RESULTS:
    We investigated the effects of Farnesol on host cells and its possible synergistic interaction with gingival epithelial cells against C. albicans infection by studying the expression of TLR2, 4 and 6. The production of IL-6, IL-8, and human β-defensins 1 and 2 was also examined using engineered human oral mucosa tissue put in contact with various concentrations of Farnesol with and without C. albicans. Our findings indicate that 24 h after contact with C. albicans, epithelial cells expressed more TLR2 than did non-infected cells. The addition of exogenous Farnesol upregulated the TLR2 expression by the gingival epithelial cells in the presence or absence of C. albicans. In contrast, TLR4 was down regulated when Farnesol was added to the tissue with or without C. albicans. Finally, Farnesol alone was shown to have no effect on TLR6, yet in the presence of both C. albicans and Farnesol, TLR6 expression was down regulated. Farnesol modulated TLR2 expression by the epithelial cells following tissue contact with C. albicans. This effect was paralleled by IL-6 but not IL-8 secretion. Farnesol’s effect on innate immunity was strengthened by its capacity to increase human β-defensin 2 production, and by the efficacy of β-defensin against C. albicans growth.
    CONCLUSIONS:
    Overall results showed that exogenous Farnesol promoted epithelial cell defense against C. albicans infection through the involvement of TLR2, IL-6, and human β-defensin 2.
    Farnesol Description
    Source:
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Vanillic acid glucoside

    Catalog No: CFN95257
    CAS No: 32142-31-7
    Price: $368/5mg
    Isoeuphorbetin

    Catalog No: CFN95207
    CAS No: 50677-55-9
    Price: $318/5mg
    3,4-O-dimethylcedrusin

    Catalog No: CFN95026
    CAS No: 166021-14-3
    Price: $388/10mg
    1,3,6-Trihydroxy-2-methylanthraqui...

    Catalog No: CFN95095
    CAS No: 87686-87-1
    Price: $218/10mg
    Cannabisin A

    Catalog No: CFN95287
    CAS No: 130508-46-2
    Price: $318/5mg
    Ginsenoside Rk2

    Catalog No: CFN92818
    CAS No: 364779-14-6
    Price: $318/5mg
    Liquiritin apioside

    Catalog No: CFN90707
    CAS No: 199796-12-8
    Price: $238/20mg
    Isovalerylshikonin

    Catalog No: CFN95222
    CAS No: 52387-14-1
    Price: $318/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 4.4984 mL 22.4921 mL 44.9843 mL 89.9685 mL 112.4606 mL
    5 mM 0.8997 mL 4.4984 mL 8.9969 mL 17.9937 mL 22.4921 mL
    10 mM 0.4498 mL 2.2492 mL 4.4984 mL 8.9969 mL 11.2461 mL
    50 mM 0.09 mL 0.4498 mL 0.8997 mL 1.7994 mL 2.2492 mL
    100 mM 0.045 mL 0.2249 mL 0.4498 mL 0.8997 mL 1.1246 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Cell Research:
    Breast Cancer Research and Treatment, 2008, 107(1):49-61.
    Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.[Pubmed: 17333335]
    Farnesoid X receptor (FXR) is a metabolic nuclear receptor expressed in the liver and traditionally considered as a bile acid sensor. Yet, FXR has been recently demonstrated in other tissues and cells, such as the kidneys, the adrenals, and arterial smooth muscle cells.
    METHODS AND RESULTS:
    Immunohistochemical data reported in this study point to the expression of FXR in human breast cancer. In addition, FXR expression was also found by Western blotting and immunofluorescence microscopy in breast-cancer-derived cell lines MCF-7 (estrogen receptor [ER]-positive) and MDA-MB-231 (ER-negative). The FXR activator Farnesol, a mevalonate pathway intermediate, exerts a mitogenic effect on MCF-7 cells. The growth stimulation is completely suppressed by antiestrogens. In contrast, MDA-MB-231 cells appear Farnesol-insensitive, suggesting an involvement of ER in Farnesol mitogenicity. In accordance with this interpretation, Farnesol induces in MCF-7 cells a decrease of ER level, consistent with a phenomenon of receptor downregulation. Farnesol also increases progesterone receptor (PgR) expression in MCF-7 cells and stimulates ER-mediated gene transactivation in MVLN cells (MCF-7 cells stably transfected with an ER reporter gene). Of note, both effects of Farnesol on ER expression and activity are completely suppressed by antiestrogens. In addition, Farnesol-induced PgR is markedly reduced by FXR gene silencing (siRNA), demonstrating the involvement of FXR in the estrogenic effects of Farnesol. Finally, coimmunoprecipitation experiments (FXR immunoprecipitation followed by Western blot analysis of ER in the immunoprecipitate) produced definite evidence that FXR interacts with ER.
    CONCLUSIONS:
    Altogether, these observations reveal the hitherto unreported presence of FXR in breast cancer and show that the latter receptor functionally interacts with ER. The occurrence of such a crosstalk calls for some caution regarding the pharmacological use of FXR agonists.